Systemic Lupus Erythematosus | Access and Reimbursement | Including Lupus Nephritis | EU5 | 2018
Thesystemic lupus erythematosus (SLE)therapy market in the five major pharmaceutical markets in Europe (EU5) is mostly served by off-label therapies.Benlysta is the only drug approved for SLE in more than 50 years, but uptake of Benlysta IV has been tempered by its high price in a largely generic market, physician perceptions of its modest efficacy, a slow onset to action, and an inability to be used in patients with severe, life-threatening organ involvement. Benlysta SC, which offers a more-convenient mode of administration,recently began to launch across the EU5, and several novel therapies are in late-stage development for SLE, including anifrolumab, atacicept, and voclosporin. In addition, both Orencia and Benlysta are being studied in lupus nephritis (LN). As these emerging agents become available, EU5 payers and prescribers must carefully balance clinical efficacy with cost-effectiveness, and drug marketers must be well equipped to navigate a complex road to reimbursement.
Questions Answered:
How do reimbursement terms for Benlysta IV and Benlysta SC vary across the EU5? How do payers regulate use of these premium-priced agents?
How do prescribing patterns for key SLE therapies differ between and within EU5 countries, and to what extent does payer policy impact uptake?
What restrictions are imposed on SLE therapies, and how, if at all, do these restrictions influence physician prescribing practices?
What key market access challenges do emerging SLE agents face? What lessons have been learned, and what market access levers can drug developers use to optimize the positioning of their products?
PRODUCT DESCRIPTION
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
Scope:
Markets covered: France, Germany, Italy, Spain, United Kingdom.
Methodology: Survey of 253 rheumatologists and country-specific interviews with 10 payers.